Introduction
Atherosclerosis is a multifactorial and multistep disease that causes coronary artery diseases, peripheral vascular diseases and stroke. Its incidence is increasing worldwide and is the major cause of death due to cardiovascular events. The earliest stage in the development of atherosclerosis is characterized by altered normal endothelial homeostatic functions, which promote the retention and oxidation of apoB-lipoproteins in the sub-endothelial space and are associated with an inflammatory response. This leads to i) the differentiation of intima-infiltrated monocytes into macrophages, causing them to accumulate cholesterol, become foam cells and eventually form a lipid core, and ii) the phenotypic modulation of smooth muscle cells, switching them from a contractile to a synthetic phenotype to promote neointimal hyperplasia. The treatment of symptomatic atherosclerosis typically involves an angioplasty with stent placement but this procedure further damages the vascular endothelium and frequently triggers thrombosis and restenosis [1] . Thus, endothelial protection and repair remain key processes to consider when developing strategies to help prevent atherosclerosis and its complications [2] .
Large prospective population studies have provided evidence that low levels of highdensity lipoprotein cholesterol (HDL-C) are a major independent cardiovascular risk factor [3] . Accordingly, pre-clinical and translational studies have also revealed that HDL particles (HDL) display multiple anti-atherogenic properties [4, 5] , with the best known property being their ability to promote cellular cholesterol efflux and the transport of cholesterol back to the liver for excretion. In addition, HDL are known to exert beneficial effects on endothelial cells, including the stimulation of nitric oxide (NO) production, the inhibition of the apoptotic action of stimuli such as TNF-α and oxidized LDL, and the promotion of cell proliferation and migration [6, 7] . However, recent results from genetic or clinical research have cast considerable doubt on the relevance of increasing HDL-C concentration per se [8] . First, Mendelian randomization studies of common genetic variants for HDL-C are inconsistent in their support for a causal relationship between HDL-C concentration and cardiovascular diseases [9, 10] . Second, in clinical trials, HDL-C raising drugs, such as nicotinic acid and CETP inhibitors, have failed to reduce cardiovascular events any more than statins administered alone [8, 11] . One argument to explain these discrepancies is that assessment solely on HDL-C might not predict the outcome of pharmacological intervention. Indeed, HDL-C concentration is a static measurement and does not reflect the dynamics or the functionality of the HDL particles, which differ according to the individual's metabolic status [12] . Thus, understanding the molecular mechanisms that underlie the biological activities of HDL will allow for more strategic approaches in the development of HDL-based therapeutics.
Interestingly, both the protein and lipid moieties of HDL contribute to their beneficial effects on endothelial cells. Early in vitro studies reported that both HDL and apolipoprotein A-I (apoA-I), the main HDL apolipoprotein, stimulate endothelial cell proliferation and migration and inhibit apoptosis [13] [14] [15] . Consistent with this, carotid artery reendothelialization following perivascular artery injury was shown to be diminished in apoA-I-null mice, with normal re-endothalialization restored by apoA-I reconstitution [16] . To date, three receptors that contribute to HDL-mediated cell survival signaling pathways have been identified on endothelial cells. First, sphingosine 1-phosphate (S1P) receptors interact with HDL-associated S1P and exert a mitogenic effect through activation of a phosphoinositide 3-kinase (PI3K)/ Akt-dependent pathway [17] . HDL also bind to scavenger receptor class B member 1 (SR-BI) to accelerate re-endothelialization through activation of the Src kinases, PI3K and p44/42 mitogen-activated protein kinases (MAPK) [16] . Finally, apoA-I binds and activates the ecto-F 1 -ATPase receptor on the surface of endothelial cells and endothelial progenitor cells (EPC), to promote cell proliferation [18, 19] . The effects of apoA-I on ecto-F 1 -ATPase activity are strictly limited to this receptor since they were observed following the inhibition of other HDL/apoA-I receptors, such as SR-BI and ABCA1, but were reduced following treatment with inhibitory factor 1 (IF1-H49K), a specific F 1 -ATPase inhibitor. Interestingly, the effects of apoA-I-induced ecto-F 1 -ATPase activity have been shown to depend on the production of extracellular ADP [18, 20] , suggesting that an ADP-sensitive P2Y receptor might be involved, as has been previously shown in hepatocytes [21] [22] [23] [24] . However, neither the P2Y receptor nor the intracellular signaling components responsible for endothelial cell proliferation downstream of ecto-F 1 -ATPase activation have been characterized.
In this study, we first sought to gain a better understanding of the signaling pathways downstream of ecto-F 1 -ATPase activation by apoA-I. Due to the central role of the PI3K/Akt pathway in HDL-mediated endothelial protection, we investigated whether this pathway was also involved downstream of apoA-I-induced ecto-F 1 -ATPase activation, and thereby influences endothelial cell proliferation. Furthermore, we investigated the involvement of different P2Y ADP receptors and PI3K isoforms in this process.
Materials and Methods

Materials
Cell culture reagents were purchased from Lonza (Walkersville, USA). Rabbit monoclonal antibodies against phosphorylated Akt (anti-pAkt Ser 473 and anti-pAkt Thr
308
), rabbit polyclonal antibodies against Akt (anti-Akt), HRP-conjugated anti-rabbit IgG antibodies and oligomycin were from Cell Signaling Technologies (Danvers, MA, USA). Rabbit polyclonal antibodies against the p110β isoform of PI3K (anti-PI3Kβ) were from Santa Cruz Biotechnology (Dallas, Texas, USA). Sphingosine-1-phosphate (S1P) and MRS2179 (a P2Y 1 antagonist) were from Sigma Aldrich (Saint Quentin Fallavier, France). PI3K inhibitors (AS-252424, wortmannin and TGX-221) were from Selleckchem (Euromedex, France). PI3Kβ siRNA (Hs_PIK3CB_5, NM_006219), P2Y 1 siRNA (Hs_P2Y1_5_HP, NM_002563) and control siRNA (Allstars Neg Control siRNA) were from Qiagen (France). The enhanced chemiluminescence (ECL) system was from Bio-Rad (Roane, France). HDL 3 , referred to as HDL throughout the manuscript, and apoA-I, were isolated from the plasma of normolipidemic healthy human donors as previously described [25] . The plasmid encoding the mutated IF 1 protein (with histidine 49 switched to lysine, referred to as IF1-H49K), which is active at all pH values, was kindly provided by J. Walker (Cambridge, UK), and protein production was carried out as previously described [26] .
Cell culture
Human umbilical vein endothelial cells (HUVECs) were cultured in EBM-2 medium containing 2% (v/v) fetal bovine serum (FBS) and growth factors (EGM-2 Bullet Kit, Lonza). Cells were seeded in collagen I-coated dishes (BD biocoat, Becton Dickinson) at a density of 5000 cells/cm 2 until 80% to 90% confluence, and used at the third through fifth passages.
Pharmacological treatments and inhibitors
Endothelial cells were grown overnight in EBM-2 medium containing 1% albumax (LifeScience, Invitrogen). The next day, unless otherwise specified, cells were pre-incubated for 30 min with F 1 -ATPase inhibitors (1 µM IF1-H49K [18] , or 125 nM oligomycin [27] ), PI3K inhibitors (wortmannin, TGX-221 or AS-252424, 100 nM each) or a P2Y 1 receptor antagonist (1 µM MRS2179), then treated for 15 min with apoA-I (100 µg/mL), HDL (50 µg/mL) or S1P (200 nM).
siRNA transfection Endothelial cells were seeded at 150,000 cells/well in a 6-well plate in growth medium without antibiotics. They were then reverse transfected using lipofectamine® RNAimax (LifeScience, Invitrogen) in Optimem medium (Gibco) with 20 nM siRNA against PI3Kβ (CCCUUCGAUAAGAUUAUUGAAUU (F) and UUCAAUAAUCUUAUCGAAGGGUU (R)), or P2Y 1 (AAGACAGGCUUCCAGUUCUACUU (F) and GUAGAACUGGAAGCCUGUCUUUU (R)). 24 h later, a second transfection was performed and 4 h after that the medium was replaced with complete growth medium. After a further 24 h, cells were serum starved overnight before treatment. Silencing efficiency was determined by western blotting for PI3Kβ and by RTqPCR for P2Y 1 .
Western blot analysis
After treatment, cells were lysed in Laemmli buffer, boiled for 5 min at 100°C, then separated by SDS-PAGE and transferred onto PVDF membranes (Immobilon-P, Millipore). Immunodetection was achieved by incubating with the relevant primary antibodies in 5% BSA overnight at 4°C: anti-pAkt Ser 473 (1:4000), anti-pAkt Thr 308 (1:1000), anti-Akt (1:4000) or anti-PI3Kβ (1:1000). HRP-conjugated anti-rabbit (1:4000) secondary antibodies were incubated for 1 h at room temperature and immunoreactive proteins were detected with ECL reagents, according to the manufacturer's instructions. Membranes were analyzed using Chemidoc (Bio-Rad), and the densities of protein bands from western blot images were quantified using Image Lab software (Bio-Rad). Values of phosphorylated Akt were normalized against the amount of total Akt. Changes in phosphorylation levels were evaluated by comparing the differences between basal (untreated cells) and stimulated (treated cells) values and were expressed as fold increase over basal.
Reverse transcription-PCR (RT-PCR) and real-time quantitative PCR (RT-qPCR)
Total RNA was extracted with the Trizol reagent (Invitrogen), then phase separation was performed with chloroform and RNA was precipitated with isopropanol. RNA concentrations were determined using a spectrophotometer. One microgram of total RNA was reverse-transcribed into first strand cDNA using hexamer. A minus-reverse transcriptase control (without the M-MLV reverse transcriptase enzyme) was performed and used as a negative control. For RT-qPCR, cDNA was then amplified by RT-qPCR with SYBR Green (Roche). The primers used to amplify RNA encoding PI3Kβ, P2Y 1 and the reference gene (ribosomal protein L27, Rpl27) were designed using the Primer Express software (Life Technologies SAS, Villebon sur Yvette, France) with the following sequences: Rpl27 (ATCGCCAAGAGATCAAAGATAA, TCTGAAGACATCCTTATTGACG), PI3Kβ (AGCTGGTTTGGATCTTCGGATG, CACAACTTCAATGAGGCCAGAGC), and P2Y 1 (TCCACAAGGCATAGCCTCCAAG, AGCAAGAGTCTTCTTCACCATGAC). All real-time PCR reactions were performed on a LC480 (Roche), with the following thermal cycling parameters: annealing at 60°C for 40 s, amplification at 95°C for 10 s and dissociation at 95°C for 10 s. The PCR program was followed by a melting curve and values were normalized according to the amount of Rpl27. C T values of Rpl27 were constant in all samples. Conventional PCR assays were carried out using the following primers: PI3Kα (GTCAATCGGTGACTGTGTGG, GACGATCTCCAATTCCCAAA), PI3Kβ (TCAGCCTTCGCTCCTAATGT, TGCAAAGTCAGCAGGAAATG), PI3Kγ (CAACGTTCCGGCAATAGTTT, CGACTGGTTTCCTTCATGGT), P2Y 1 (CTGATACGTGGCATAAACCC, GTTCAATTTGGCTCTGGCCG), P2Y 12 (TGGGAACAGGACCACTGAGA, GGGTGTAAGGAATTCGGGCA), and P2Y 13 (CTCAGCAATGCCTTCCTGGA, GGCCAGAAAGGTAGGCAAGT). PCR amplification was carried out on equal amounts of cDNA for 35 cycles for PI3K isoforms and 45 cycles for P2Y receptors, using the following parameters: initial denaturation step, 2 min at 95°C; amplification steps, 30 s at 58°C (PI3Ks) or 66°C (P2Ys) and 30 s at 72°C; and final elongation step, 30 min at 72°C. Amplification products were resolved on a 2% agarose gel and stained with ethidium bromide. Fragment sizes were determined by comparison with known DNA standards.
Proliferation assay
Cells were seeded at a density of 25,000 per 6-well plate and grown for 24 h in complete medium. Cells were then washed twice with PBS, incubated in control medium (EBM-2 + 2% FBS) and treated with or without apoA-I (100 µg/mL), and with or without TGX-221 (100 nM) or MRS-2179 (1 µM, twice a day). Cells were allowed to grow for a further 48 h, then were washed twice with PBS and harvested with trypsin to be counted with a Beckman Coulter Counter.
Statistical analysis
For the analysis of variance between groups of data, one-way ANOVA was performed followed by the Bonferroni test, using GraphPad Prism 5.0 (GraphPad Software). Results are expressed as means ± SEM, with differences considered significant at p < 0.05.
Results
ApoA-I induces Akt phosphorylation
To investigate whether the PI3K/Akt pathway is involved in signal transduction by apoA-I in endothelial cells (HUVECs), we analyzed the phosphorylation of Akt following treatment with apoA-I and HDL. Kinetic and dose response experiments both revealed that apoA-I induced phosphorylation of Akt at its activation sites, threonine 308 (Thr308) and serine 473 (Ser473), within 5 min of stimulation (Fig. 1A) , with a maximum phosphorylation observed at 100 µg/mL (Fig. 1B) . Similar effects were observed when cells were incubated with HDL (Fig. 1C, D) . Our results show that, compared to unstimulated cells, the maximum increase in Akt Ser473 phosphorylation induced by apoA-I and HDL was 40 ± 2 and 46 ± 8 fold, respectively (Fig. 1B and 1D ). These results indicate that apoA-I and HDL activate PI3K/ Akt at similar levels.
Akt phosphorylation induced by apoA-I occurs through ecto-F1-ATPase activation
We and others have found that ecto-F 1 -ATPase is expressed at the cell surface of endothelial cells and acts as an apoA-I receptor [18] [19] [20] 28] . To investigate whether ecto-F 1 -ATPase is involved in apoA-I-induced Akt phosphorylation, endothelial cells were treated with 1 µM IF1-H49K, a selective protein inhibitor of F 1 -ATPase activity, which has been previously shown to inhibit the effect of apoA-I on endothelial cell proliferation at this concentration [18] . As reported in Fig. 2A , cell treatment with IF1-H49K dramatically decreased (∼93%) the phosphorylation of Akt induced by apoA-I (100 µg/mL) whereas a low level of Akt phosphorylation persisted in HDL-stimulated cells treated by IF1-H49K. Interestingly, IF1-H49K did not affect S1P-induced phosphorylation of Akt ( Fig. 2A) . Since S1P activation involves S1P receptors [17] , these results demonstrate that IF1-H49K specifically inhibits Akt phosphorylation induced by an apoA-I receptor. Similar results were also obtained with oligomycin ( Fig. 2B) , another inhibitor of F 1 -ATPase activity [27, 29] . Altogether, these results indicate that Akt phosphorylation induced by apoA-I in endothelial cells is driven solely through ecto-F 1 -ATPase activity.
The P2Y1 receptor is involved downstream of ecto-F1-ATPase activation by apoA-I
ApoA-I binding to ecto-F 1 -ATPase stimulates its ATPase activity and generates extracellular ADP [30] . We previously reported that ADP and its analogues (2MeSADP and ADPβS) but not its hydrolysis products (such as AMP and adenosine), promote endothelial cell survival in a similar manner to apoA-I [18] , suggesting that extracellular ADP generated from the stimulation of ecto-F 1 -ATPase by apoA-I activates an ADP-sensitive P2Y receptor. We thus analyzed whether an ADP receptor of the P2Y family was involved in Akt phosphorylation downstream of F 1 -ATPase activation by apoA-I. P2Y receptors are G protein-coupled receptors (GPCR) and three of them are preferentially activated by ADP, namely P2Y 1 , P2Y 12 and P2Y 13 [31, 32] . Due to the lack of specificity of all commercial antibodies tested against P2Y receptors, we analyzed the expression of P2Y 1 , P2Y 12 and P2Y 13 receptors by assessing mRNA levels (Fig. 3A) . As previously reported in HUVECs [33] , we found that P2Y 1 mRNA was clearly detected, whereas P2Y 12 and P2Y 13 mRNA were barely detectable. As a control, and as previously reported [21] , we observed that mRNA for P2Y 1 and P2Y 13, but not P2Y 12 , were present in the hepatoma cell line HepG2 (Fig. 3A) .
To assess whether the P2Y 1 receptor is involved in Akt phosphorylation downstream of ecto-F 1 -ATPase activation by apoA-I, HUVECs were pretreated with MRS2179, a selective P2Y 1 antagonist [33] , before cell stimulation with apoA-I. Figure 3B shows that MRS2179 strongly decreased the phosphorylation of Akt induced by apoA-I. Furthermore, this effect was specific to apoA-I since Akt phosphorylation induced by S1P was unchanged following MRS2179 treatment (Fig. 3B) . In order to ascertain the role of the P2Y 1 receptor in transducing apoA-I signaling, HUVECs were transfected with siRNA against P2Y 1 (Fig. 3C) . The results show that P2Y 1 gene silencing (by up to 80%; Fig. 3B, inset) , caused the complete inhibition of Akt phosphorylation induced by apoA-I (Fig. 3C) . These data indicate that the P2Y 1 ADP receptor is involved in Akt phosphorylation downstream of ecto-F 1 -ATPase activation by apoA-I.
PI3Kβ mediates Akt phosphorylation induced by apoA-I
To further elucidate the signaling pathway mediating the effects of apoA-I activation in endothelial cells, we next sought to determine which isoform of PI3K is involved in apoA-I-induced Akt phosphorylation downstream of ecto-F 1 -ATPase and P2Y 1 receptor activation. Endothelial cells have been shown to express the α, and γ isoforms of class I PI3Ks [34] , and PCR analysis confirmed the presence of mRNA for these three isoforms in HUVECs (Fig. 4A) . Quantitative real time PCR indicated that the α and β isoforms were highly expressed whereas the γ isoform was expressed to a lesser extent (not shown). We chose to specifically investigate the respective roles of the β and γ isoforms of PI3K in apoA-I-induced Akt phosphorylation since previous studies have shown that these are the main isoforms activated downstream of GPCR activation [35, 36] . Endothelial cells were treated with either wortmannin, a pan-PI3K inhibitor, or with selective PI3Kβ (TGX-221) or PI3Kγ (AS-252424) inhibitors. We observed that the inhibition of PI3Kβ by TGX-221 abrogated the phosphorylation of Akt induced by apoA-I to the same extent as that of wortmannin, whereas the PI3Kγ inhibitor did not affect Akt phosphorylation (Fig. 4B) . Moreover, transfection of HUVECs with siRNA directed against PI3K p110β (Fig. 4C) showed that silencing of the p110β subunit of PI3Kβ (by up to 80%, assessed by western blotting, data not shown) completely inhibited apoA-I-induced Akt phosphorylation whereas a control siRNA had no effect. Altogether, these results demonstrate that PI3Kβ, and not PI3Kγ, is involved in apoA-I-induced Akt phosphorylation in endothelial cells. 5 . The PI3Kβ isoform mediates endothelial cell proliferation induced by free apoA-I. HUVECs were grown for 24 h in complete medium, then incubated in EBM-2 medium + 2% FBS either alone (control) or with apoA-I (100 µg/ml). Under each of these conditions, cells were also treated or not with the P2Y 1 antagonist MRS2179 (1 µM, twice a day) or the PI3Kβ inhibitor TGX-221 (100 nM). Cells were grown for 48 h, washed twice with PBS, harvested with trypsin and then counted with a Beckman Coulter Counter. Values are expressed as the percentage of cells per well compared to the control condition. Data are presented as means ± SEM (n = 6-9 wells per group). Data with different subscripted letters indicate significant differences, tested by one-way ANOVA followed by the Bonferroni post-hoc test, with p<0.05.
Pharmacological inhibition of the P2Y1 receptor and PI3Kβ activity inhibits apoA-Iinduced endothelial cell proliferation
Finally, we sought to establish the relevance of the P2Y 1 /PI3Kβ axis downstream of apoA-I-induced ecto-F 1 -ATPase activation by investigating its role in endothelial cell proliferation induced by apoA-I. HUVEC cells were pretreated with the P2Y 1 antagonist, MRS2179, the PI3Kβ inhibitor, TGX-221, or vehicle controls. The proliferation of cells grown in control medium alone (EBM-2 + 2% FBS, basal proliferation) was then compared with medium containing apoA-I (Fig. 5) . As previously reported [18] , we confirmed that adding apoA-I (100 µg/mL) to control medium promoted endothelial cell proliferation by more than 20%. We then observed that MRS2179 and TGX-221 treatment prevented these positive effects of apoA-I on endothelial cell proliferation. Interestingly, TGX-221 inhibited cell proliferation (by 35%) independently of apoA-I stimulation, indicating that PI3Kβ activity contributed to the basal proliferation of endothelial cells. Conversely, endothelial cell proliferation mediated by P2Y 1 receptors was strictly dependent on apoA-I activation since MRS2179 had no effect on basal cell proliferation. Altogether, these results indicate that apoA-I activates the ecto-F 1 -ATPase receptor to stimulate endothelial cell proliferation through activation of the P2Y 1 receptor and the PI3Kβ/Akt pathway.
Discussion
In this study, we have demonstrated that the PI3K/Akt signaling pathway is involved downstream of ecto-F 1 -ATPase stimulation by apoA-I in HUVECs. ApoA-I binding to ecto-F 1 -ATPase was previously shown to promote endothelial cell proliferation in an ADP-dependent manner [18] , and we provide evidence here that signal transduction mediated by the apoA-I/ ecto-F 1 -ATPase axis depends specifically on the P2Y 1 ADP-receptor and involves the p110β PI3K class I isoform (PI3Kβ).
Endothelial cells express several receptors that bind to HDL and their main apolipoprotein, apoA-I [7, 37] . Among these, ABCA1 and ecto-F 1 -ATPase are known to bind to lipid-poor apoA-I with high affinity, whereas ABCG1 and SR-BI only interact with mature HDL particles [7, 18, 38] . Both ecto-F 1 -ATPase and ABCA1 contribute towards HDL transcytosis [20, 39] , an important process that depends on an intact endothelium and allows HDL to reach the subendothelial space of the arteries [7] . Besides their involvement in HDL transcytosis, ecto-F 1 -ATPase and ABCA1 each have specific effects on endothelial cells. Notably, endothelial ABCA1 promotes cholesterol efflux to apoA-I and activates antiinflammatory signaling pathways [7, 40, 41] , (Vaisman et al. 2012 ) whereas ecto-F 1 -ATPase activity promotes apoA-I-induced endothelial cell survival [18] . Furthermore, cholesterol efflux to HDL mediated by endothelial ABCG1 was shown to display non redundant functions than ABCA1 by promoting preservation of eNOS activity and suppression of endothelial inflammation in vivo [41] . Additionally, endothelial SR-BI signaling in response to HDL has been shown to involve the activation of Src and AMPK, which in turn activate the PI3K/Akt/ MAPK pathways to facilitate secretion of vasodilating factors, including nitric oxide (NO) and prostacyclin (PGI 2 ), as well as endothelial cell proliferation and migration [16, 37] . The PI3K/Akt/MAPK signaling pathways are also activated in endothelial cells by sphingosine 1 phosphate (S1P), a bioactive phospholipid preferentially associated with apoM in HDL particles, which binds to endothelial S1P 1 and S1P 3 receptors. This has been shown to lead to eNOS activation and endothelial cell migration and survival [37, 42] . In the present work, we specifically targeted ecto-F 1 -ATPase signaling by using lipid-free apoA-I, thereby excluding HDL-induced cell signaling through the SR-BI and S1P receptors. We show that lipid-free apoA-I activates a PI3K/Akt pathway that solely depends on the ecto-F 1 -ATPase receptor, as evidenced by the complete inhibition of apoA-I-induced Akt phosphorylation by ecto-F 1 -ATPase inhibitors. In addition to lipid-free apoA-I, ecto-F 1 -ATPase binds to mature HDL particles [25, 30] and, accordingly, HDL-induced Akt phosphorylation was partially inhibited by ecto-F 1 -ATPase inhibitors, with the remaining level of phosphorylated Akt likely attributed to signaling downstream of SR-BI or S1P receptors. Thus, ecto-F 1 -ATPase, SR-BI and S1P receptors all activate PI3K/Akt signaling pathways in response to HDL. This raises the question of whether these receptors cooperate or can compensate for each other in signal transduction induced by HDL. It has been suggested that the binding of HDL to SR-BI may provide a molecular platform for efficient receptor stimulation by HDL-associated S1P [37] , but whether and how ecto-F 1 -ATPase, SR-BI and S1P receptors interact in endothelial cells will need further investigation.
Previous studies have highlighted the close partnership between the stimulation of ecto-F 1 -ATPase activity by apoA-I and P2Y ADP receptor signaling [32] . P2Y receptors are G protein-coupled receptors (GPCRs) that are activated by adenine and uridine nucleotides [43] . All of the three P2Y receptors that are preferentially activated by ADP (P2Y 1 , P2Y 12 and P2Y 13 ) have been found to be coupled to ecto-F 1 -ATPase activity and display different functions depending on the cell type [32] . For instance, in hepatocytes the apoA-I/ecto-F 1 -ATPase/P2Y 13 axis activates an intracellular RhoA/ROCKI signaling pathway that stimulates HDL uptake and appears to have atheroprotective properties by promoting reverse cholesterol transport [21-24, 30, 44, 45] , and in adipocytes HDL-apoA-I, ecto-F 1 -ATPase and P2Y signaling are all involved in lipid metabolism [46] [47] [48] [49] [50] . In endothelial cells, apoA-I/ecto-F 1 -ATPase has been previously shown to stimulate HDL transcytosis via activation of P2Y 12 ADP receptors [20] . This study was performed on bovine aortic endothelial cells (BAECs) expressing both the P2Y 1 and P2Y 12 receptors and the authors used specific antagonists for each of these P2Y receptors to show that only P2Y 12 is involved in HDL transcytosis. In our study, we used HUVECs that express high levels of P2Y 1 but barely detectable levels of P2Y 12 and P2Y 13 (Fig. 3A and [33] ), allowing us to specifically study P2Y 1 downstream of apoA-I/ ecto-F 1 -ATPase. Our data show that pharmacological inhibition and gene silencing of P2Y 1 fully inhibited apoA-I-induced Akt phosphorylation, indicating that the P2Y 1 receptor alone contributes to apoA-I/ecto-F 1 -ATPase-induced PI3K/Akt signaling in this cell type. Moreover, apoA-I-induced cell proliferation was also completely blocked following pharmacological inhibition of the P2Y 1 receptor. It is thus likely that in endothelial cells ecto-F 1 -ATPase is coupled to both the P2Y 1 and P2Y 12 receptors, the expression levels of which depend on the cell type, and that their activation promotes cell proliferation and HDL transcytosis respectively.
Some beneficial properties of endothelial P2Y 1 receptors in the vasculature have already been reported. For instance, using pharmacological approaches, different studies have evidenced that P2Y 1 contributes to ADP-induced vasodilatation of intact arteries through the release of dilating factors such as NO and PGI 2 [51, 52] . Furthermore, P2Y 1 receptors have been shown to promote ADP-mediated endothelial cell migration in vitro [33] . However, some other studies have suggested a role for endothelial P2Y 1 in adhesion molecule-dependent leucocyte recruitment in femoral arteries after the induction of acute inflammation by TNFα [53, 54] . Thus, P2Y 1 receptors may have opposite functions in vascular endothelial protection depending on the inflammatory status and stages of atherosclerotic development. In addition to these functions, we provide evidence for a role of endothelial P2Y 1 in cell proliferation downstream of ecto-F 1 -ATPase activation by apoA-I. Our work has focused on identifying the intracellular signal transduction involved in this process and thus further investigation is required to determine whether activation of endothelial P2Y 1 by apoA-I/ecto-F 1 -ATPase promotes other cellular responses, such as secretion of vasodilating factors and cell migration.
In terms of the cell signaling pathways downstream of apoA-I-induced ecto-F 1 -ATPase/ P2Y 1 activation, we found here that it specifically involves the class I PI3K (PI3K) β isoform. This result is supported by a recent study demonstrating that endothelial PI3Kβ promotes endothelial repair in vivo [55] . PI3Kβ is composed of a p110 catalytic and a p85 regulatory subunit, the latter being activated by tyrosine kinase receptors [56] , however this kinase seems to be preferentially activated downstream of GPCR activation [36] . Accordingly, our study demonstrated that the PI3Kβ isoform -and not the γ isoform -is responsible for Akt phosphorylation and cell proliferation in apoA-I-stimulated endothelial cells. It has been proposed that activation of PI3Kβ requires the synergistic activation of both the β and γ G protein subunits as well as a phosphotyrosyl peptide [57, 58] . We cannot exclude the possibility that, in endothelial cells, apoA-I stimulation induces tyrosine kinase activation through ecto-F 1 -ATPase to recruit PI3Kβ downstream of P2Y 1 receptor activation, but the nature of this tyrosine kinase remains to be identified. PI3Kβ has also been reported to be essential in S1P-stimulated endothelial cells [59, 60] , suggesting that this kinase is a central protein in HDL-induced endothelial cell proliferation through its role downstream of different receptors, such as S1P receptors or ecto-F 1 -ATPase. Moreover, PI3Kβ has been reported to mediate NO production in endothelial cells following the activation of different receptors [59, 61] . As mentioned above, both HDL and P2Y 1 can also contribute to NO secretion in endothelial cells and it could thus be of great interest to further investigate the possible involvement of the HDL/P2Y 1 /PI3Kβ axis in eNOS activation and the respective contributions of these different HDL receptors in this process.
Recently, class II PI3Ks have also been demonstrated to be important for HDL signaling. These PI3Ks have been investigated to a much lesser extent than the class I PI3Ks and their roles are not well understood [62] , however it seems that class II PI3Ks play an important function in HDL signaling downstream of S1P receptor activation. Although the molecular mechanisms leading to the activation of class II PI3Ks are not clearly understood, it was reported that GPCRs can activate this class of PI3K [62] . Therefore, we cannot exclude the possibility that, through activation of a P2Y receptor, apoA-I could also activate a class II PI3K that regulates other biological processes such as endothelial cell migration and survival.
The number of different PI3K isoforms led us to question whether each isoform has a different role within endothelial cells. This question is particularly relevant since pharmaceutical industries have started to develop isoform-specific PI3K inhibitors. Our results clearly identify that PI3Kγ is not involved downstream of apoA-I-induced cell signaling mediated through endothelial ecto-F 1 -ATPAse. PI3Kγ is a well-known mediator of inflammation in arterial walls through its roles in both immune cell signaling [63, 64] and in endothelial cells where it can modulate the E-selectin pathway necessary for leucocyte recruitment [65] . The identification of a beneficial role of PI3Kβ in endothelial cells confirms the specific role of these different PI3K isoforms in vascular diseases [34] and demonstrates that these two isoforms of PI3K may play opposite roles in a physiopathological context and especially in vascular diseases. PI3K is known to have an important role in platelet aggregation, and specific PI3Kβ inhibitors prevent the formation of stable α IIb β 3 integrin adhesion contacts, leading to defective platelet thrombus formation. In vivo, the use of these inhibitors eliminates occlusive thrombus formation but does not prolong bleeding time [66] [67] [68] , identifying the PI3Kβ isoform as a useful target in the development of antithrombotic therapies. Since our study suggests that PI3Kβ is also important for endothelial protection induced by HDL-apoA-I, it seems necessary to now evaluate the in vivo effects of PI3Kβ inhibition on re-endothelialization before proposing this kinase as a valid pharmacological target for antithrombotic therapy in patients.
To conclude, the present study demonstrates that signal transduction downstream of endothelial ecto-F 1 -ATPase activation by HDL-apoA-I occurs through the specific activation of the P2Y 1 ADP receptor and involves a PI3Kβ/Akt signaling pathway. Moreover, we have identified that this signaling module is responsible for HDL-apoA-I-induced endothelial cell proliferation. Thus, this work has identified a novel signaling pathway which may contribute to the atheroprotective functions of HDL-apoA-I. Future in vivo research must now evaluate whether this pathway contributes to the repair, or re-endothelialization, of an endothelial lesion.
